Zynex: Deteriorating Fundamentals and Signs of Reimbursement Pressure – Night Market Research
Zynex: Deteriorating Fundamentals and Signs of Reimbursement Pressure – Night Market Research
Revenue growth masks deteriorating profitability: operating margins trend lower (64% lower past two years) as Zynex accelerates hiring in face of early signs of reimbursement pressure. Tricare becomes first large health plan since Medicare to drop ZYXI’s device for one of its largest indications citing poor efficacy - we expect other payors to follow Zynex…
ZYNEX: ALTERING THE MEDICAL INDUSTRY IN “NON-INVASIVE” WAYS
Zynex: Abusive Pricing Model Unsustainable (NASDAQ:ZYXI)
Midmark IQvitals® Zone™ 4-000-0722 Wireless Monitor, with Serenity
ZYXI: A case study - by Adu Subramanian
Zynex: Abusive Pricing Model Unsustainable (NASDAQ:ZYXI)
Zynex: Turnaround Nears End – UnitedHealthcare Cuts TENS
Zynex: Turnaround Nears End – UnitedHealthcare Cuts TENS
US Medical Device Regulations - APCER Life Sciences
Michael Franzone - Zynex Medical
Zynex: Deteriorating Fundamentals and Signs of Reimbursement
Device-Based Treatment in Hypertension: At the Forefront of Renal
Survey details payers' concerns in covering new and expensive
